

Xanthus Life Sciences Appoints John A. McCarthy, Jr. as Senior Vice President and Chief Financial Officer

CAMBRIDGE, Mass., Sept. 23 /PRNewswire/ -- Xanthus Life Sciences, Inc., a privately-held oncology drug development company, today announced that John A. McCarthy, Jr. has joined the Xanthus management team as Senior Vice President and Chief Financial Officer.

"John brings to Xanthus tremendous leadership skills in our industry and the financial, operations and investor relations experience needed to take our company to the next level," stated Richard T. Dean, Ph.D., President and CEO of Xanthus. "We are pleased to continue to attract high caliber talent such as John. The strength of our team is enabling us to execute on our business strategy while making important contributions to the field of oncology and personalized dosing of medications."

John McCarthy joins Xanthus from Synta Pharmaceuticals Corp. where he was Senior Vice President and Chief Financial Officer. Prior to Synta, Mr. McCarthy was at Exact Sciences Corporation where he served as Executive Vice President and Chief Financial Officer. Mr. McCarthy joined Exact Sciences in 2000 as a privately-held company and shortly thereafter led its successful initial public offering and subsequent public financing. Additionally, Mr. McCarthy was instrumental in developing the strategic corporate partnerships and operational infrastructure necessary for the company's national launch of its first commercial product in 2003. Prior to Exact Sciences, Mr. McCarthy's healthcare experience included serving as President of InfoMedtrics Corporation (privately-held), President of the Managed Care Division of Concentra Managed Care, Inc. (publicly-traded), and SVP and CFO of MedChem Products, Inc. (publicly-traded). Additionally, Mr. McCarthy's prior experience included serving as an investment banking associate with Morgan Stanley. Mr. McCarthy is a graduate of Lehigh University and Harvard Business School. Mr. McCarthy serves on the Board of Directors of Signet Laboratories, Inc.

About Xanthus

Xanthus is an oncology drug development company. Xanthus' small molecule candidates are Xanafide(TM), Symadex(TM) and Clomet(TM) which are advancing in clinical and preclinical development for multiple cancer indications. Each of these product candidates was in-licensed based on significant clinical and/or preclinical data supporting safety and activity. Xanthus also has proprietary technology to individualize patient dosing, which it believes may help improve the performance of certain drugs in development, and facilitate the life cycle management of certain marketed products, without limiting patient populations or markets.

Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec. More information is available at <http://www.xanthus.com>.

Contacts:

Kari Watson, MacDougall Biomedical Communications, Inc.
kwatson@macbiocom.com or (508) 647-0209

Richard T. Dean, Ph.D., Chief Executive Officer, Xanthus Life Sciences
(617) 225-0522

SOURCE Xanthus Life Sciences, Inc.

-0- 09/23/2005

/CONTACT: Kari Watson of MacDougall Biomedical Communications, Inc.,
+1-508-647-0209, kwatson@macbiocom.com; or Richard T. Dean, Ph.D. of Chief
Executive Officer of Xanthus Life Sciences, Inc., +1-617-225-0522/

/First Call Analyst: /

/FCMN Contact: /

/Web site: <http://www.xanthus.com> /